Paul D Morrison
Affiliation: King's College London
- SchizophreniaPaul D Morrison
Department of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
Curr Biol 15:R980-4. 2005
- Cannabis, the mind and society: the hash realitiesRobin M Murray
Institute of Psychiatry, Psychological Medicine, De Crespigny Park, Denmark Hill, London, SE5 8AF, UK
Nat Rev Neurosci 8:885-95. 2007....
- Cannabis use and psychiatric and cogitive disorders: the chicken or the egg?Marta Di Forti
Department of Psychological Medicine, Institute of Psychiatry, London, UK
Curr Opin Psychiatry 20:228-34. 2007..Cannabis is the world's most commonly used illicit drug. In this review, we consider the recent literature on the effects of cannabis on mental health and on cognition...
- Does intravenous Δ9-tetrahydrocannabinol increase dopamine release? A SPET studyEmma Barkus
Institute of Psychiatry, Kings College London, London, UK
J Psychopharmacol 25:1462-8. 2011..THC did not lead to a significant increase in DA release even though the dose was sufficient for participants to have psychotic symptoms. These findings do not support a central role for striatal DA in THC-elicited psychosis...
- Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedationP D Morrison
Kings College London, The Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
Hum Psychopharmacol 26:77-80. 2011..It is unknown if cannabis recreates the negative symptoms of schizophrenia...
- Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptomsPaul D Morrison
The Biomedical Research Centre, Institute of Psychiatry, King s College London, Denmark Hill, UK
Neuropsychopharmacology 36:827-36. 2011..The results reveal that the pro-psychotic effects of THC might be related to impaired network dynamics with impaired communication between the right and left frontal lobes...
- From real-world events to psychosis: the emerging neuropharmacology of delusionsPaul D Morrison
Institute of Psychiatry, King s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK
Schizophr Bull 35:668-74. 2009..Here, we discuss how the 3 modulators regulate learning within the striatum and how their dysfunction may lead to delusional thinking...
- The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioningP D Morrison
Institute of Psychiatry, The Biomedical Research Centre, King s College London, UK
Psychol Med 39:1607-16. 2009..In a study of intravenous (i.v.) synthetic THC in healthy humans, we aimed to study the relationship of the psychotic symptoms induced by THC to the consequent anxiety and neuropsychological impairment...
- What is the mechanism whereby cannabis use increases risk of psychosis?Sonija Luzi
Institute of Psychiatry, Division of Psychological Medicine, Denmark Hill, London, SE5 8AF, UK
Neurotox Res 14:105-12. 2008..This paper starts to consider the neurochemical mechanisms whereby cannabis use increases the risk of psychosis...
- Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairmentAmir Englund
The Biomedical Research Centre, Institute of Psychiatry, King s College London, UK
J Psychopharmacol 27:19-27. 2013..6 ± 18.9%) compared with the CBD group (-0.4% ± 9.7 %) (t=2.39, p<0.05). These findings support the idea that high-THC/low-CBD cannabis products are associated with increased risks for mental health...
- Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathologySagnik Bhattacharyya
Section of Neuroimaging, Division of Psychological Medicine and Psychiatry, Institute of Psychiatry, King s College London, London, UK
Neuropsychopharmacology 35:764-74. 2010..Delta-9-THC and CBD can have opposite effects on regional brain function, which may underlie their different symptomatic and behavioral effects, and CBD's ability to block the psychotogenic effects of Delta-9-THC...
- Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective reviewJames M Stone
King s College London Institute of Psychiatry, London, UK
J Psychopharmacol 21:440-52. 2007..We consider the case for glutamatergic excitotoxicity as a key process in the development and progression of schizophrenia, and suggest ways in which glutamate and dopamine dysregulation may interact in the condition...
- Cannabis in the arm: what can we learn from intravenous cannabinoid studies?Amir Englund
King s College London, Institute of Psychiatry, Denmark Hill, London SE5 8AF
Curr Pharm Des 18:4906-14. 2012..Here in a critical review, we appraise the major findings from recent intravenous cannabinoid studies in humans and trace the historical roots of this work back to the 1970's...
- Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of lightAlessandra Paparelli
Division of Psychological Medicine, Institute of Psychiatry, King s College London London, UK
Front Behav Neurosci 5:1. 2011..In this review we examine the main hypotheses resulting from the link observed between the most common psychotomimetic drugs (lysergic acid diethylamide, amphetamines, cannabis, phencyclidine) and schizophrenia...
- Schizophrenia: more evidence for less glutamatePaul D Morrison
Institute of Psychiatry, De Crespigny Hill, London SE5 8AF, UK
Expert Rev Neurother 7:29-31. 2007..These findings underscore the importance of NMDA receptors in schizophrenia and support therapeutic strategies aimed at boosting glutamate transmission...